Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lowered its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 9.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 215,473 shares of the biotechnology company’s stock after selling 23,166 shares during the quarter. California State Teachers Retirement System owned 0.14% of Ironwood Pharmaceuticals worth $3,398,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ameriprise Financial Inc. acquired a new stake in shares of Ironwood Pharmaceuticals during the second quarter worth about $1,472,000. Oppenheimer Asset Management Inc. raised its position in shares of Ironwood Pharmaceuticals by 592.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 17,878 shares of the biotechnology company’s stock worth $338,000 after purchasing an additional 15,295 shares during the period. Russell Investments Group Ltd. raised its position in shares of Ironwood Pharmaceuticals by 40.7% during the third quarter. Russell Investments Group Ltd. now owns 143,082 shares of the biotechnology company’s stock worth $2,256,000 after purchasing an additional 41,406 shares during the period. First Trust Advisors LP raised its position in shares of Ironwood Pharmaceuticals by 20.3% during the second quarter. First Trust Advisors LP now owns 94,732 shares of the biotechnology company’s stock worth $1,789,000 after purchasing an additional 16,018 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Ironwood Pharmaceuticals by 3.6% during the second quarter. The Manufacturers Life Insurance Company now owns 104,571 shares of the biotechnology company’s stock worth $1,974,000 after purchasing an additional 3,681 shares during the period.

IRWD has been the topic of a number of research analyst reports. ValuEngine raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 29th. BidaskClub lowered Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 30th. Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 4th. Bank of America lowered Ironwood Pharmaceuticals from a “buy” rating to an “underperform” rating and dropped their target price for the company from $20.00 to $15.00 in a research report on Friday, January 5th. Finally, Zacks Investment Research raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 18th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $17.56.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total transaction of $927,000.00. Following the transaction, the insider now owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Peter M. Hecht sold 113,405 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the transaction, the chief executive officer now directly owns 4,696,917 shares in the company, valued at approximately $71,017,385.04. The disclosure for this sale can be found here. Insiders have sold a total of 175,769 shares of company stock worth $2,679,491 in the last ninety days. Insiders own 7.63% of the company’s stock.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded down $0.64 during trading on Wednesday, reaching $14.81. The company had a trading volume of 2,120,225 shares, compared to its average volume of 2,111,553. The firm has a market cap of $2,396.08, a price-to-earnings ratio of -15.27 and a beta of 1.45. Ironwood Pharmaceuticals, Inc. has a 1-year low of $13.59 and a 1-year high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. The firm had revenue of $86.80 million for the quarter, compared to analyst estimates of $73.59 million. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.18) EPS. analysts anticipate that Ironwood Pharmaceuticals, Inc. will post -1.08 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/31/california-state-teachers-retirement-system-decreases-holdings-in-ironwood-pharmaceuticals-inc-irwd.html.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply